Marker Therapeutics Files 8-K on Financials

Ticker: MRKR · Form: 8-K · Filed: Mar 31, 2025 · CIK: 1094038

Marker Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyMarker Therapeutics, Inc. (MRKR)
Form Type8-K
Filed DateMar 31, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, company-update

TL;DR

Marker Therapeutics dropped its 8-K for March 31, 2025, detailing financials. Check it out.

AI Summary

Marker Therapeutics, Inc. filed an 8-K on March 31, 2025, reporting on its results of operations and financial condition. The filing details the company's financial statements and exhibits. Marker Therapeutics, formerly known as TAPIMMUNE INC. and GENEMAX CORP, is incorporated in Delaware and based in Houston, Texas.

Why It Matters

This 8-K filing provides an update on Marker Therapeutics' financial performance and condition, which is crucial information for investors to assess the company's stability and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial results and does not appear to contain any significant new risks or adverse information.

Key Players & Entities

  • Marker Therapeutics, Inc. (company) — Registrant
  • TAPIMMUNE INC. (company) — Former company name
  • GENEMAX CORP (company) — Former company name
  • 20250331 (date) — Report date
  • Houston, Texas (location) — Company address

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Marker Therapeutics, Inc.'s Results of Operations and Financial Condition, including Financial Statements and Exhibits.

When was this 8-K report filed?

This 8-K report was filed on March 31, 2025.

What were Marker Therapeutics, Inc.'s former names?

Marker Therapeutics, Inc. was formerly known as TAPIMMUNE INC. and GENEMAX CORP.

Where is Marker Therapeutics, Inc. located?

Marker Therapeutics, Inc. is located at 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, Texas, 77021.

What is Marker Therapeutics, Inc.'s fiscal year end?

Marker Therapeutics, Inc.'s fiscal year ends on December 31 (1231).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 31, 2025 regarding Marker Therapeutics, Inc. (MRKR).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.